Related Experiment Video
Updated: Jul 3, 2026

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
Published on: March 1, 2024
Administration of antibiotics via the respiratory tract as monotherapy for pneumonia
Matthew E Falagas1, Michalis Agrafiotis, Zoe Athanassa
1Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece. m.falagas@aibs.gr
Abstract:
There is increasing interest in applying alternatives to the systemic modes of administration of antimicrobial agents for the treatment of patients with pneumonia. We endeavored to accumulate and evaluate the published evidence on the role of aerosolized antimicrobials administered as monotherapy for patients with pneumonia through searches of PubMed, Scopus and relevant bibliographies. Seven relevant studies (one randomized controlled trial, four case series and two case reports), including 63 patients, were identified; 37% (23 out of 63) and 63% (40 out of 63) of these patients suffered from community-acquired and nosocomial (including ventilator-associated) pneumonia, respectively. Acinetobacter baumannii (41%), Gram-positive cocci (37%) and Pseudomonas aeruginosa (16%) were the pathogens most frequently isolated from sputum, tracheal aspirates, bronchoalveolar lavage and bronchial brush specimens. Colistin (49%), penicillin (37%) and aminoglycosides (17%) were the antimicrobials administered via the respiratory tract. Concurrent systemic antimicrobials (without activity against the isolated pathogens) were given to 33% (21 out of 63) of patients. Clinical cure and bacteriological eradication from the aforementioned specimens were observed in 86% (54 out of 63) and 85% (33 out of 39) of patients, respectively. For the 31 patients for whom data were available, all-cause mortality and attributable mortality were 36% (11 out of 31) and 10% (three out of 31), respectively. The very limited published data preclude any strong conclusions; however, the available data seem to suggest that aerosolized antimicrobial monotherapy for pneumonia should not be a priori excluded when systemic access is unavailable, denied by the patient or when concerns exist regarding bioavailability in the lungs or systemic toxicity. Clinicians are encouraged to publish any relevant experience in order for a considerable body of literature to be accumulated.
Insights
Aerosolized antimicrobial monotherapy shows promise for pneumonia treatment when systemic options are limited. While data are scarce, it offers a viable alternative for certain patient cases.
Area of Science:
- Pulmonology
- Infectious Diseases
- Pharmacology
Background:
- Growing interest in alternative antimicrobial administration routes for pneumonia.
- Systemic administration has limitations, prompting exploration of other methods.
Purpose of the Study:
- To evaluate published evidence on aerosolized antimicrobial monotherapy for pneumonia.
- To assess the efficacy and safety of inhaled antimicrobials as a standalone treatment.
Main Methods:
- Systematic literature search of PubMed, Scopus, and bibliographies.
- Inclusion of seven studies (RCT, case series, case reports) involving 63 pneumonia patients.
- Analysis of pathogens, administered antimicrobials, and patient outcomes.
Main Results:
- Predominant pathogens included Acinetobacter baumannii, Gram-positive cocci, and Pseudomonas aeruginosa.
- Colistin, penicillin, and aminoglycosides were common inhaled agents.
- High rates of clinical cure (86%) and bacteriological eradication (85%) were observed.
Conclusions:
- Limited data suggest aerosolized antimicrobial monotherapy is a potential option when systemic therapy is not feasible.
- Consideration is warranted for cases with unavailable systemic access, patient refusal, or concerns about lung bioavailability/systemic toxicity.
- Further research and publication of clinical experiences are encouraged to build a stronger evidence base.
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Atypical Pneumonia
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment
